Ecraprost

Summary

Ecraprost (CHEMBL2104574) is a phase-3 clinical-stage small molecule; indicated across 1 condition including peripheral vascular disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Chemistry: 480.7 Da · C28H48O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104574
Name	Ecraprost
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6917049
Molecular formula	C28H48O6
Molecular weight	480.7
InChIKey	HITYEEHTEOQBAC-OSIGYOHNSA-N

SMILES: CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=C1CCCCCCC(=O)OCCCC)OC(=O)CCC)O)O

IUPAC name: butyl 7-[(4R,5R)-2-butanoyloxy-4-hydroxy-5-[(E,3S)-3-hydroxyoct-1-enyl]cyclopenten-1-yl]heptanoate

Also known as: AS-013, Circulase, Ecraprost, ECRAPROST

Patent coverage: 30 distinct patent families (56 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
peripheral vascular disease	3	MONDO:0005294	EFO:0003875

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).